Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients

J Clin Oncol. 2007 Apr 10;25(11):1455-6. doi: 10.1200/JCO.2006.08.7080.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alkaline Phosphatase / blood
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Aromatase Inhibitors / adverse effects
  • Aromatase Inhibitors / therapeutic use*
  • Biomarkers / blood
  • Biomarkers / urine
  • Bone Density / drug effects*
  • Breast Neoplasms / blood
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Canada
  • Chemotherapy, Adjuvant
  • Collagen Type I / blood
  • Collagen Type I / urine
  • Estrogen Receptor Modulators / administration & dosage
  • Female
  • Fractures, Bone / etiology*
  • Humans
  • Letrozole
  • Middle Aged
  • Nitriles / therapeutic use*
  • Peptides / blood
  • Peptides / urine
  • Tamoxifen / administration & dosage*
  • Treatment Outcome
  • Triazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Biomarkers
  • Collagen Type I
  • Estrogen Receptor Modulators
  • Nitriles
  • Peptides
  • Triazoles
  • collagen type I trimeric cross-linked peptide
  • Tamoxifen
  • Letrozole
  • Alkaline Phosphatase